Lynparza (olaparib) — United Healthcare

Initial criteria

• Diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal cancer
• Disease is advanced, persistent, or recurrent
• Presence of deleterious or suspected deleterious germline BRCA-mutation
• Patient has been treated with two or more prior lines of chemotherapy

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Lynparza therapy

Approval duration

12 months